Metabolic HealthResearch PaperPaywall

GLP-1 Drugs Show Links to Lower Mortality in Adults With Alcohol Use Disorder

A large observational study links GLP-1 prescriptions to fewer deaths and hospitalizations in adults with excess weight and alcohol use disorder.

Sunday, November 15, 2026 0 views
Published in Eur J Intern Med
A physician discussing a prescription injection pen with a middle-aged patient in an examination room

Summary

Could weight loss medicines also improve outcomes in adults with alcohol use disorder? Researchers examined health records from 163,681 adults with overweight or obesity and alcohol use disorder, including 10,445 who started a GLP-1 drug. After accounting for measured differences between groups, starting treatment was associated with 80% lower odds of death, 72% lower odds of hospitalization for any cause, and 28% lower odds of major cardiovascular events at one year. Alcohol-related hospitalizations were also less common. These are differences in odds, not absolute risk reductions, and the study cannot prove the drugs caused better outcomes. The findings support further clinical trials, not prescribing these medicines specifically for alcohol use disorder based on this evidence alone. This summary is based on the abstract only.

Detailed Summary

Alcohol use disorder can shorten life and increase cardiovascular risk, particularly when combined with excess weight. GLP-1 receptor agonists, medicines used for diabetes and weight management, may offer benefits beyond weight loss. A large observational study explored whether starting these drugs was associated with fewer hospitalizations, cardiovascular events, and deaths in this population.

Researchers analyzed electronic health records from 163,681 adults with overweight or obesity and alcohol use disorder. Their average age was approximately 54, and 35.6% were women. Among them, 10,445 started a GLP-1 drug. Researchers used statistical weighting to balance measured baseline differences between those prescribed treatment and those without prescriptions.

At one year, starting treatment was associated with 72% lower odds of hospitalization for any cause, 80% lower odds of alcohol-related hospitalization, and 80% lower odds of death. The odds of major cardiovascular events were 28% lower. Exploratory analyses found similar associations at three and five years. These percentages describe relative odds, not absolute risk reductions.

The findings support further trials testing whether GLP-1 drugs can improve outcomes in adults with both excess weight and alcohol use disorder. They do not establish that these medicines reduce drinking or explain why outcomes differed. For patients already considering these drugs for established indications, the study provides a useful discussion point rather than a new treatment recommendation.

This summary is based on the abstract only. Prescriptions do not confirm medication use, and unmeasured differences in health behavior, care access, or illness severity could influence results. Different follow-up starting points between groups also raise concerns about timing bias. Absolute event rates, individual drug effects, and safety results were not reported in the abstract. Randomized trials are needed before interpreting these large associations as treatment benefits or prescribing GLP-1 drugs specifically to directly treat alcohol use disorder in routine clinical practice today.

Key Findings

  • Among 163,681 adults with excess weight and alcohol use disorder, 10,445 started a GLP-1 drug.
  • At one year, GLP-1 initiation was associated with lower hospitalization odds: 72% for any cause and 80% for alcohol-related causes.
  • Death odds were 80% lower, while major cardiovascular event odds were 28% lower; these are not absolute risk reductions.
  • Exploratory three- and five-year analyses showed consistent associations, but the observational design cannot establish causation.
  • Discuss GLP-1 treatment for established indications; these findings alone do not justify prescribing it specifically for alcohol use disorder.

Methodology

This retrospective TriNetX electronic health record study included adults enrolled during 2015–2024, with follow-up through December 2025. Researchers used propensity-score-based inverse probability weighting and weighted logistic regression to compare one-year outcomes after GLP-1 initiation versus no prescription. Participants had overweight or obesity and alcohol use disorder, with exclusions including prior GLP-1 use, cancer, and non-nicotine substance use disorder diagnoses.

Study Limitations

This summary is based on the abstract only, which does not provide absolute event rates, detailed safety findings, or individual drug results. Residual confounding, prescription-versus-use uncertainty, and different follow-up starting points could bias the associations. The observational design cannot establish causation, and the exclusions limit generalizability.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: